Search

Purpose. To investigate the association between high-normal preconception TSH levels and reproductive outcomes in infertile women undergoing the first fresh D3 embryo transfer. Methods. This was a retrospective study. Euthyroid patients undergoing the first fresh D3 embryo transfer from January 2018 to May 2019 were initially included. The patients were divided into a low-TSH (0.27–2.5 mIU/L) group and a high-normal TSH (2.5–4.2 Miu) group. The reproductive outcomes were compared between the groups. Results. A total of 1786 women were ultimately included, in which 1008 of whom had serum TSH levels between 0.27 and 2.5 mIU/L and 778 of whom had serum TSH levels between 2.5 and 4.2 mIU/L. The patients were highly homogeneous in terms of general characteristics. High-normal TSH levels had no adverse impact on the clinical pregnancy rate, miscarriage rate, or live birth rate (respectively, aOR = 0.92, 1.30, and 0.88 and P = 0.416, 0.163, and 0.219). No significant differences were observed in terms of gestational age, single live birth rates, and birth weight, or birth length. Conclusion. High-normal TSH levels did not significantly influence reproductive outcomes in infertile women undergoing the first fresh D3 embryo transfer. Further studies are needed to test whether the results might be applicable to a wider population. [ABSTRACT FROM AUTHOR]

Purpose. To investigate the association between high-normal preconception TSH levels and reproductive outcomes in infertile women undergoing the first single fresh D5 blastocyst transfer. Methods. This was a retrospective study. Euthyroid patients undergoing the first single fresh D5 blastocyst transfer from January 2018 to May 2019 were initially included. The patients were divided into a low TSH (0.27–2.5 mIU/L) group and a high-normal TSH (2.5–4.2 mIU/L) group. The reproductive outcomes were compared between the groups. Results. A total of 824 women were ultimately included, 460 of whom had serum TSH levels less than 2.5 mIU/L and 364 of whom had serum TSH levels between 2.5 and 4.2 mIU/L. The patients were highly homogeneous in terms of general characteristics. High-normal TSH levels had no adverse impact on the clinical pregnancy rate, miscarriage rate, or live birth rate (respectively, aOR = 0.84, 0.65, 0.61, and P = 0.234 , 0.145, 0.083). No significant differences were observed in terms of gestational age, single live birth rates, birth weight, or birth length. Conclusion. High-normal TSH levels did not significantly influence reproductive outcomes in infertile women undergoing the first single fresh D5 blastocyst transfer. Further studies are needed to test whether the results might be applicable to a wider population. [ABSTRACT FROM AUTHOR]

Objective. To evaluate the impact of preconceptional serum TSH levels on the clinical outcomes of infertile patients undergoing their first IUI treatment cycle. Method. This was a retrospective study. Euthyroid patients undergoing the first cycle of IUI treatment from Jan 2017 to Aug 2018 were included. The patients were divided into a normal high TSH level (2.5–4.0 mIU/L) group and a low TSH level (0.4–2.5 mIU/L) group. Then, different factors were included separately to compare the outcomes between normal high and low TSH levels. The primary outcomes were clinical pregnancy rates, implantation rates, and miscarriage rates. The secondary outcomes were obstetric outcomes such as single live birth rates, birth length, birth weight, and duration of gestation. Results. Initially, 1856 patients were included, and 371 patients were excluded for different reasons. A total of 1485 patients were finally included in the analysis. The general parameters between normal high and low TSH levels were similar except for infertile duration and female BMI, which were, however, significantly different between AID-IUI patients and AIH-IUI patients (P = 0.005 and P = 0016). No significant differences were found in terms of either primary outcomes or secondary outcomes. Conclusion. Normal high-serum TSH levels within the reference range (0.4–4.0 mIU/L) measured before treatment seemed to have no adverse impact on the clinical outcomes of patients undergoing their first IUI treatment cycle. [ABSTRACT FROM AUTHOR]